Single Dose of Psychedelics May Boost Memory, Study Finds
A single dose of a novel psychedelic compound significantly improved memory and learning in mice for weeks, according to a new study from the University of Michigan. The findings, published in Nature, reveal that the compound 25CN-NBOH triggered lasting cognitive enhancements, pointing to potential new treatments for neurological and psychiatric disorders. Let’s take a look at what this can mean for all of us.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Key Takeaways from the Study
| Point | Details |
|---|---|
| Institution | University of Michigan, led by neuroscientist Omar Ahmed |
| Compound Tested | 25CN-NBOH, a selective serotonin 2A receptor agonist |
| Effect Duration | Up to three weeks of enhanced cognitive performance after a single dose |
| Cognitive Benefits | Improved reversal learning and mental flexibility |
| Biological Mechanism | Increased synaptic plasticity in key brain circuits |
| Potential Uses | Therapeutic approaches for depression, PTSD, and cognitive decline |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Not Just a Short-Term Trip
Researchers administered a single dose of 25CN-NBOH to mice and evaluated them in a series of learning and memory tasks over several weeks. The mice outperformed control groups in tests requiring adaptability and spatial memory—skills typically impaired in conditions like depression and Alzheimer’s.
Dr. Omar Ahmed, the study’s lead author, explained that even brief interventions can rewire the brain.
The compound activates serotonin 2A receptors, which promote neural plasticity. Classic psychedelics like LSD and psilocybin also target these same receptors.
A New Approach to Cognitive Therapy
What sets this study apart is the lasting nature of the effects. Most current therapies for cognitive disorders rely on ongoing medication. Here, a single treatment led to changes that endured well beyond the compound’s presence in the body. This introduces the possibility of designing short-course psychedelic-inspired therapies that carry long-term benefits.
25CN-NBOH is not currently approved for human use, and the research is still in early stages. But unlike traditional psychedelics, this compound may be less likely to cause hallucinogenic effects. Which could ease regulatory hurdles and safety concerns.
